Literature DB >> 33398242

Potential therapeutic approaches of microRNAs for COVID-19: Challenges and opportunities.

Alieh Farshbaf1,2, Nooshin Mohtasham3, Reza Zare3, Farnaz Mohajertehran3,2, Seyed Abdolrahim Rezaee4.   

Abstract

The coronavirus disease 2019 (COVID-19) emerges as current outbreak cause by Novel Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2). This infection affects respiratory system and provides uncontrolled systemic inflammatory response as cytokine storm. The main concern about SARS-CoV-2 pandemic is high viral pathogenicity with no specific drugs. MicroRNAs (miRs) as small non-coding RNAs (21-25 ​nt) regulate gene expression. The SARS-CoV-2 encoded-miRs affect human genes that involved in transcription, translation, apoptosis, immune response and inflammation. Also, they alter self-gene regulation and hijacked host miRs that provide protective environment to maintain its latency. On the other hand, Host miRs play critical role in viral gene expression to restrict infection. Over expression/inhibition of miRs might result in cell cycle irregularity, impaired immune response or cancer. In this manner, exact role of each miR should be specified. Mimic encoded-miRs like antagomirs showed successful result in phases of clinical trial prevent from negative effects of viral encoded-miRs. Products of mimic miRs are inexpensive corresponds to synthesis of primer; they are short and nanoscale in size. Although SARS-CoV-2 genome is undergoing evaluation, detection of exact molecular pathogenesis open up opportunities to for vaccine development. Salivaomics can evaluate SARS-CoV-2 genome, transcriptome, proteome and biomarkers like miRs in oral related and cancer disease. In this review, we studied the challenge and opportunities of miRs in therapeutic approach for SARS-CoV-2 infection, then overviewed the role of miRs in saliva droplet during SARS-CoV-2 infection and related cancer.
© 2021 Craniofacial Research Foundation. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; Saliva biomarker; Therapeutic approach; microRNA

Year:  2020        PMID: 33398242      PMCID: PMC7772998          DOI: 10.1016/j.jobcr.2020.12.006

Source DB:  PubMed          Journal:  J Oral Biol Craniofac Res        ISSN: 2212-4268


Introduction

Novel Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) that emerges as current viral outbreak is caused by beta coronavirus, a member of Coronaviridae family. The current disease caused by SARS-CoV-2 was termed coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). The SARS-CoV-2 spread globally since December 2019 following animal-to-human cross-species transmission. It was identified by next generation sequencing in January 2020 as seventh human coronavirus after 229E, OC43, NL63, HKU1, SARS-CoV and Middle East respiratory syndrome (MERS) types. SARS-CoV (in 2002–2003, China), MERS (in 2012, Saudi Arabia) and SARS-CoV-2 (2019, Wuhan city, China) are caused by beta coronaviruses that affects respiratory system by binding to the angiotensin converting enzyme 2 (ACE2) receptor in lung. For this reason, symptoms of upper respiratory tract reveals. Clinical symptoms are various following SARS-CoV-2 infection, most of the patient present fever, dry cough and tiredness. In addition, dyspnea, lung invasive lesions in chest radiographs, loss of smell or taste senses, ache and pains and diarrhea are observed. Based on the first genome sequencing information, SARS-CoV-2 is a positive single strand RNA (+ssRNA) with 29891 ​nt length genome and low GC content that encoding 9860 amino acid. The genome of SARS-CoV-2 be made up 11 open reading frames (ORFs) encode 16 nonstructural proteins and structural protein including spike glycoprotein (S), membrane (M), small envelope (E), nucleocapsid (N) and six accessory proteins (3a, 6, 7a, 7b, 8, and 10). The spike protein play crucial role in viral infection because its receptor binding domains (RBDs) connected to the ACE2 receptor in mucosa cell and entry into the host cell and result in pneumonia. Release a large number of systemic pro-inflammatory cytokine and chemokine by immune host cell following stimulated secretion of viral invasion provide deadly uncontrolled systemic inflammatory response. This cytokine storm including IL-6, TNFα, IL-1β, IL-8 and IL2R result in Acute Respiratory Distress Syndrome (ARDS) that is the main cause of death in COVID-19 patients. Current evidence approved SARS-CoV-2 genome got mutations that almost are point mutation. Position of mutation affect RNA secondary structure and cryptic splice site that help to virus avoided to target by host microRNAs and provide viral fitness. MicroRNAs (miRs) are non-coding RNAs, small endogenous molecules (21–25 ​nt length), that regulate gene expression by inhibition of translation process or mRNA degradation depending upon their complementarity. They play a key role post-transcriptionally by binding to 3ʹ UTR of specific target mRNAs. It is demonstrated that more than half human mRNA transcripts are regulated by miRs and a single mRNA can target by multiple miRs and controversy one miR can bind to several target mRNAs. More than 2500 miRs are involved in human gene regulation that involve in various biological pathway like proliferation, differentiation, cancer, development, cell death and metabolism. In addition, previous studies declared host miRs play critical role in viral infection by modulate virus pathogenesis. To induce this antiviral effects, miRs can bind to both 3ʹ UTR and protein coding region of virus transcripts and alter viral tissue tropism or replication, transcription and translation. On the other hand, viral-encoded miRs modulate self-gene regulation and also affect host gene expression. This can provide protective environment for life cycle of virus and maintain its latency. In this manner, some viruses able to escape from host immune response and can survive. Viral and host miRs interaction provide a cross talk between two regulatory systems result in infection. So, understand of this novel miR regulatory system can evident therapeutic approach. The main concern about SARS-CoV-2 pandemic is high viral pathogenicity with no specific drugs that increased mortality rate and threat human health. Moreover, none of previous infection exhibited pandemic health crisis like SARS-CoV-2. Although there is a complicated interaction between host cell and viral infection but detection of molecular SARS-CoV-2 pathogenesis help us to find out more new ways of therapeutic approaches. In this review, we investigate the molecular pathogenesis of SARS-CoV-2 that provide by miRs regulatory system as small non-coding RNAs that produce in virus and host cells and then overview the role of miRs in saliva droplet during SARS-CoV-2 infection and related cancers. The effects of SARS-CoV-2 encoded-miRs on human and viral target genes: So far, more than 300 viral miRs are detected which affect host and self-gene expression. The first viral encoded-miRs identified in Epstein - Barr virus (EBV) infected cells that regulate gene expression involved in immune response. Previous studies demonstrated some viruses encoded miRs that downregulate crucial genes involve in cell process and induce lung infection. It was forecasted among 90 mature SARS-CoV-2 encoded miRs that bind to 3′ UTR region of human genes, 40 miRs banded to 73 human genes. Result of gene ontology (GO) analysis showed these genes play role in Notch signaling, DNA endodeoxyribonuclease and deoxyribonuclease activities, cellular response to peptide hormone stimulus and modulation of fatty acid metabolism. The mentioned pathways participate in apoptosis process that helps to development of viral infection. The virus applies some strategy to defeat apoptotic defense. For example, cation transport regulator-like protein 1 (CHAC1) gene as proapoptotic enzyme that involve in Notch signaling is target by SARS-CoV-2 encoded miR named as MD2-5p. Another gene, RAD9A -as a checkpoint in cell arrest during DNA damage and repair requirement-interact with BAX and Bcl-2 and targeted by MR147–3p. It was demonstrated SARS-CoV-2 miRs silence P53, as an apoptosis inducer, and BMPR2 genes that involve in pathogenesis of respiratory infection. Other study predicted 26 mature SARS-CoV-2 miRs affect human genes in apoptosis and also EGF, FGF receptor signaling, angiogenesis and VEGF pathway. Likewise, it was shown 30 viral miRs can target 1367 human genes in transcription, metabolism, immune system and some pathway like Wnt and EGFR. Some SARS-CoV-2 encoded-miRs affect human genes are listed in Table 1.
Table 1

List of selected SARS-CoV-2-encoded miRs target host gene.

miRTarget geneUp/down RegulationTissueEffectRef.
nCoV-MD3 -3Pp53DowninsilicoSubvert the key role of p53 in suppress of viral replication, pulmonary vascular homeostasis and upregulation of IFN I result in respiratory infection17
nCoV-MD241–3PBMPR2DowninsilicoReduce expression of innate immune response genes like IFN I and result in respiratory infection17
MD2-5pCHAC1DowninsilicoIt interfered with pro-apoptotic enzyme activity and apoptosis process15
MR147–3pRAD9ADowninsilicoAs a checkpoint, it interfered to cell arrest when DNA damaged and need to repaired15
MR147–3pTMPRSS2UpGutPromote infection24
MR385–3pTGFBR3UpInnate and adaptive immune cellsIt boost Th1 differentiation and modulate regulatory T-cell activation and survival46
MR359–5pMYH9 and ITGB5UpAll tissue except heart for MYH9 geneCytoskeleton proteins are critical for viral replication and life cycle and help virus for surfing, internalization,and migration within the cell15
MR66–3pTNF-αUpSpleenTNF-α as a key cytokines provides “cytokine storm” during inflammation15
MR147–3pTMPRSS2UpGutAs a biological membrane interfered with maintain of intestine equilibrium i.e., transporting ions, small molecules, and macromolecules and present gastrointestinal symptoms15
MR198–3pADARUpLiverIt suppress IFN system responses in viral infections and manifest signs of liver damage15
MR328–5pRXRAUpLung, spleen, gut, liverIt reduced host antiviral effect following IFN-I suppression15
List of selected SARS-CoV-2-encoded miRs target host gene. It was reported SARS-CoV-2 encoded miRs can target 5ʹ UTR of human genes like promoter and enhancer regions and activated gene expression. More upregulation of gene expression is observed in immune response specially chemokine signaling and cytoskeleton related protein. Also, among various tissues that infected by SARS-CoV-2 lung is more gene targeted by viral miRs and spleen and gut go after lung. In addition, alignment of SARS-CoV-2 encoded-miRs and human miRs with high similarity showed they are involved in same pathway that affects pathophysiology, inflammation and clinical features. Overall, the host gene expression can alter in SARS-CoV-2-infected cells in compare to normal. For instance, among 124 selected genes, upregulation of 104 genes and downregulation of 20 genes were observed and analysis of different pathway detected target genes are involved in inflammation response and manifestation of clinical pathogenesis. To prevent negative effects of viral encoded-miRs on host genes, antagomirs showed successful result in phases of clinical trial for viral infection like miR-122 in hepatitis C infection.

The effect of human encoded-miRs on SARS-CoV-2 pathogenesis and infection

Host miRs play pivotal role in progression of viral infection. It was shown cellular miRs act as anti-viral host defense and modulated viral infection. The interaction of host miRs and viral genome result in inhibition of translation or stabilization of viral RNA that prevent from replication. Previous studies suggested human miRs play anti-viral role against viral infection such as HIV-1, HCV, CMV, influenza and dengue. One of the challenges is viral escape from host inhibition following several ways: 1) block host miRs function, 2) avoidance to be target by host miRs following own 3′ UTR sequence modification with mutation or length shortness that cannot bind complementary, 3) provide secondary structure with too long 3′ UTR sequence. Another challenge is hijacked host miRs that help virus to modulate cell biological process, also function of target genes affect by hijacked miRs can alter similarly. It was assumed 28 human miRs hijacked by SARS-CoV-2 and affects more than 800 genes. Most of this hijacked human miRs predicted significantly interfering with immune response in COVID-19 patients. CDC reported 80% of COVID-19 related death is observed among adult individuals ≥65 years with severe outcome in United States. It was predicted one of the probable reason that aged adult present sever COVID-19 or more mortality is miR expression levels go down. It was assumed SARS-CoV-2 can replicate and produce essential particles parallels low overall miR expression in aged individuals similar to previous reports. It should be consider some illness like cardiovascular and lung related disease can alter expression of human miR repertoires significantly, so affect SARS-CoV-2 and host cell interaction. This is one of the reasons that some people are classified as high risk groups that should be more careful about their self. Some problems with COVID-19 patients like oxygen dependent, ventilation needs and Shortness of breath increase pulmonary hypertension and chronic lung diseases that linked to miR-1307–3p involved in TGF-β signaling. It has been proposed miR-1307 as a therapeutic target in SARS-CoV-2 infection because TGF-β play crucial role in lung development and mentioned diseases. It was suggested 3 critical human miRs can apply for COVID-19 therapeutic strategies because they bind complete complementary to SARS-CoV-2 gRNA without any side effect on host genes, they are miRs 5197–3p, 4778–3p and 6864–5p. The miRs 5197–5p was identified especially as more effective on viral infection such as SARS-CoV, MERS-CoV and COVID-19 and also propose for hepatitis B and herpes simplex virus (HSV-1) infections. In Table 2 we listed some altered human encoded-miRs expression and related genes affected in SARS-CoV-2 infection in lung.,
Table 2

Human top ranked miRs expression in lung during COVID-19 progression.

miRTarget geneUp/down RegulationEffect
miR-8066-PRLR, CXCL6, IL6, IL17, IL10 and ACVR1-TGF-β pathway, mucin type O-Glycan and cytokine-cytokine receptor interaction-chemokine binding receptors- FGFR pathwayUp-Activate NfKB to target pro-inflammatory cytokines and induce cytokine storm-Increased NfKB mediated TLR-8 expression-Change N-glycosylation patterns-Upregulation of FGFR pathways
miR-5197–3pTGF-β, mucin type O-Glycan and cytokine-cytokine receptor interactionUp-Similar to miR-8066-And also GABAergic synapse, morphine addiction and metabolism of xenobiotics by cytochrome P450
miR-3611GABAergic synapse, morphine addiction and metabolism of xenobiotics by cytochrome P450Down-Probably promote viral replication
miR-1468–5pTGF-1 and MAPKs signallingUp-Cardiac fibrosis
miR-1307–3pTGF-β and semaphorin signallingUp-Promote inflammatory responses
miR-3691–3pTGF-signalling, FGF2 and VCAM1Down-Lung pathogenesis
miR-3934–3pTGFBR1 and SMAD3Down-Affect glycosaminoglycan biosynthesis-heparan sulfate/heparin, other types of O-glycan biosynthesis and vitamin digestion-absorption mechanisms
Human top ranked miRs expression in lung during COVID-19 progression.

The role of miRs as saliva biomarker in pathogenesis of viral infection and cancer

Microdroplets are tiny particles (10 ​μm) carrying the SARS-CoV-2 and can transmit to others via exhale, loud conversation and sneezing. As mention above, expression of miRs can alter in different condition like viral infection or cancer. Moreover, miRs are present in liquid body such as saliva, tear, urine and plasma. One of the reasons that is used the plasma from recovered COVID-19 patients is presence of antiviral miRs in addition to antibodies following previous SARS-CoV-2 infection. In viral infection, like SARS-CoV-2, profile of miR expression change and investigation of this alternation can obtain by liquid body such as saliva. Saliva collection provides advantage including rapid, non-invasive, stable diagnosis with reliable indication and early diagnosis before signs appear. In addition, an advanced technique named “salivaomics” can evaluate genome, transcriptome, proteome and biomarkers such as miRs in oral related and cancer disease. The human miRs can use as biomarkers for viral infection and cancer diagnosis, because they are regulator and impact gene related expression. In Table 3 we mentioned some human miRs target SARS-CoV-2 genome and involve in cancer. In this manner, they can be utilized for prognostic approach. Up to date, some studies approved implement of miRs as biomarkers in head and neck squamous cell carcinomas (HNSCCs) including Oral, hypopharyngeal, esophageal and tongue squamous cell carcinomas. We previous reported the validity of saliva biomarkers presence in HNSCC in compare to blood and other tissues.30, 31, 32 The salivary miRs are extricated from normal or tumor cells and also during apoptosis or emitted of exosome or microvesicles. They demonstrated high potential utility in disease monitoring. For example, profile of salivary miR expression identified significant decreasing of miR-139 in tongue SCC in compare to control group. Furthermore, the levels of miR-139 expression return to normal after surgery and indicated miR-139 play tumor suppressor role with biomarker potential. Interestingly, outcome of a diagnostic validity study demonstrated 93% overall agreement in saliva specimen in compare to nasopharyngeal aspirate in detection of viral respiratory infection like SARS-CoV-2.
Table 3

List of selected human miRs target SARS-CoV-2 genome and involve in cancer progression.

miREffectRef.
miR-197–5pCardiovascular disease47
miR-338–3pLiver, lung and gastric cancers48, 49, 50
miR-4778–3pCervical cancer radioresistance51,52
miR-6864–5pUrothelial Carcinoma of the Bladder51,53
miR-5197–3pSquamous cell lung carcinoma51,54
miR-15b-5pCoronary Artery Disease55
miR-15a-5pKidney disease56
miR-548c-5pColorectal Cancer57
miR-548d-3pOsteosarcoma58
miR-409–3pOsteosarcoma59
miR-30b-5pEsophageal squamous cell carcinomaDiabetic retinopathy60,61
miR-505–3pProstate cancer62
miR-520c-3pObesity/diabetes63
miR-30e-3pMyocardial Injury64
miR-23cHepatocellular carcinoma65
miR-30d-5pNon-small cell lung cancer66
miR-4684–3pColorectal cancer67
miR-518a-5pGastrointestinal tumors68
miR-5197Non-small cell lung cancer (NSCLC), HTLV-1, HIV-1, Ebola69, 70, 71, 72
miR-3611Chronic obstructive pulmonary disease (COPD)HIV-1 infection73
miR-3934Colon cancer, lung cancer, NSCLC, rectal carcinoma mucosa74, 75, 76
miR-1307Severity of pulmonary hypertension in systemic scleroderma77
miR-3691–3pChronic obstructive pulmonary disease78
miR1468–5pGlioma, hepatocellular carcinoma, Alzheimer’s disease79, 80, 81
List of selected human miRs target SARS-CoV-2 genome and involve in cancer progression.

Discussion

Current evidence approved microRNAs affect regulation of viral gene expression to restrict infection. In this review, we studied the challenge and opportunities of miRs as smallest non-coding RNAs in SARS-CoV-2 infection. The dual role of host miRs cannot be declined, they can play role as antiviral regulatory factors and also interact with viral miRs that benefice for virus replication and propagation. Based on insilico analysis seems first function is more possible, but in vitro and in vivo studies are needed to validate obtained data. It was detected difference of gene expression between healthy and SARS-CoV-2 infected lung cells associated with regulatory role of miRs in some crucial pathways, like as TGF-β. Alternation in TGF-β pathway stimulates host response as cytokine storm and affect immune defense, and also cause clinical features. Increasing of host miRs to target SARS-CoV-2 genes like S, M, N, E and ORF1ab will be obstruct viral entry and replication. In Fig. 1 we mentioned some human miRs target SARS-CoV-2 genome that product structural protein. As well, reduction of host miRs provides environment for more viral replication and accessibility for the host immune system. So, modification of host-miR levels alters specific cellular processes that are crucial for control of infection. Therapeutic approach based on replacement of mimic miRs can apply to increase low host miR levels to suppress viral infection or take modified miRs products that cannot be degraded and uptake from the cells effectively. Previous studies indicated intranasal inhalation of mimic miRs protect animal from viral respiratory infection., Target delivery with least toxicity is crucial in miR-based therapeutic strategies. It should be considered over expression/inhibition of miRs might result in cell cycle irregularity, impaired immune response or cancer. In this manner, exact role of each miR should be specified.
Fig. 1

Selected human miRs target SARS-CoV-2 genome that product structural protein. S protein: bind to host cell receptor, consist of two subunits; S1 define virus-host range and cellular tropism, S2 modulates virus-cell membrane fusion. E protein: form hydrophilic pores on host membranes in addition to viral recognition and pathogenesis. M protein: Three transmembrane proteins bind to nucleucapsid. N protein: Produce two domains that binding to viral RNA genome.

Selected human miRs target SARS-CoV-2 genome that product structural protein. S protein: bind to host cell receptor, consist of two subunits; S1 define virus-host range and cellular tropism, S2 modulates virus-cell membrane fusion. E protein: form hydrophilic pores on host membranes in addition to viral recognition and pathogenesis. M protein: Three transmembrane proteins bind to nucleucapsid. N protein: Produce two domains that binding to viral RNA genome. Although result of genome analysis estimated ~78.7% sequence homology between SARS-CoV and COVID-19, but target of host miRs for both viral genomes can significantly be difference. Recent study demonstrated 848 and 873 human miRs target SARS and COVID-19 genomes respectively that only 588 common human miRs target both viral sequences. Also, they estimated only 315 miRs were unique for isolated COVID-19 that obtained from different geographical region. Recent studies evaluated SARS-CoV-2 strain mutations in different geographical region and find out viral genome get more mutated. Mutations mediate host immune response and affect virus survival with more pathogenicity. Furthermore, evolution of SARS-CoV-2 genome helps virus to overcome host antiviral response special miRs as essential regulatory molecular pathway. On the other hand, virus can get advantage of host miRs to suppress own replication to escape from immune response but promote its transmission stronger. After successful transmission, the virus can rapidly mutate own strains to elevate host specificity to avoid host miRs interaction following RNA polymerase activity without proofreading. Altogether 810 mutations are discovered in SARS-CoV-2 genome consists of 646 SNPs, 19 indels, 145 deletions and also 33 sequence of pre-miRs overlapped with these mutations. And also, more than half mutation was predicated synonym and most of them were substitution of C/G to U. Outcome of these variations might attenuate phenotype of SARS-CoV-2 with reducing viral miRs repertories and affect miR-binding site and their regulatory role in defense mechanism. Detection of new SARS-CoV-2 mutations should be considered because genetic variation in SARS-CoV-2 genome prevent from vaccine development. Similarly, this virus is undergoing evolution, natural selection effect and purifying selection, so detection and evaluation of exact molecular pathogenesis open up opportunities to apply best therapeutic approaches. There are challenges in modification of host miR levels or replacement of mimic miRs that should be considered their side effects. Selected miRs should be effective, safe and well tolerated by patients. Moreover, design and products of mimic miRs are inexpensive corresponds to synthesis of primer sequence, they are short and nanoscale in size that can deliver by exosomes. The protein-protein interaction network between human and SARS-CoV-2 was identified by affinity-purification mass spectrometry, the outcome of this study can help us to focus on miRs that target translation inhibitors and sigma 1, 2 receptors.

Conclusion

The effects of miR based therapeutic approaches approved in viral infection. Alternation in human miRs expression including overexpression or mimic replacement, inhibition or suppression helps to block viral entry or replication in host cells. Target SARS-CoV-2 genes such as S, M, N, E and ORF1ab by increasing host miRs attenuate viral latency. In contrast, decreasing in human miRs against SARS-CoV-2 infection provide more viral replication and accessibility for immune system. The crucial challenge for selection of candidate human miRs against SARS-CoV-2 infection is the side effects following alternation of gene. More investigation assists to least the side effects. On the other hand, the impact of SARS-CoV-2 encoded-miRs on host genes should not be ignored. As a solution, potential therapeutic of antagomirs as the small molecular inhibitors can be evaluated for SARS-CoV-2 infection. The stability, effective delivery, higher binding affinity and uptake with less degradation by nuclease are the common problem in target miRs therapy process. The SARS-CoV-2 genome sequence discovery and its alignment with the other correlated Coronaviridae family help us to help from previous therapeutic approaches. Salivaomics present high potential utility in detection of biomarker such as miRs; it can help in vaccine development for SARS-CoV-2.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of competing interest

The authors declare that there are no conflicts of interest.
  78 in total

Review 1.  MicroRNAs as mediators of viral evasion of the immune system.

Authors:  Bryan R Cullen
Journal:  Nat Immunol       Date:  2013-02-15       Impact factor: 25.606

2.  Differential expression of microRNA and arachidonic acid metabolism in aspirin-treated human cardiac and peri-cardiac fat-derived mesenchymal stem cells.

Authors:  Diana T Ruan; Song Gao; Harnath Shelat; Bridgette King; Yong-Jian Geng
Journal:  Vascul Pharmacol       Date:  2020-02-07       Impact factor: 5.773

3.  The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis.

Authors:  Yingchun Liang; Xiaojie Xu; Tao Wang; Ying Li; Wenye You; Jing Fu; Yang Liu; Shuai Jin; Quanbo Ji; Wei Zhao; Qi Song; Ling Li; Tian Hong; Junjian Huang; Zhaohui Lyu; Qinong Ye
Journal:  Cell Death Dis       Date:  2017-07-13       Impact factor: 8.469

Review 4.  Epstein-Barr virus-encoded microRNAs as regulators in host immune responses.

Authors:  Man Wang; Fei Yu; Wei Wu; Yu Wang; Han Ding; Lili Qian
Journal:  Int J Biol Sci       Date:  2018-04-05       Impact factor: 6.580

5.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

6.  MicroRNA Regulatory Network as Biomarkers of Late Seizure in Patients with Spontaneous Intracerebral Hemorrhage.

Authors:  Ifeanyi Iwuchukwu; Doan Nguyen; Michelle Beavers; Vi Tran; Wale Sulaiman; Erin Fannin; Lindsay Lasseigne; Eugene Ramsay; Jason Wilson; Nicolas G Bazan
Journal:  Mol Neurobiol       Date:  2020-02-10       Impact factor: 5.590

7.  COVID 19 can spread through breathing, talking, study estimates.

Authors:  Ramananda Ningthoujam
Journal:  Curr Med Res Pract       Date:  2020-05-08

8.  Overexpression of High-Mobility Motor Box 1 in the Blood and Tissues of Patients with Head and Neck Squamous Cell Carcinoma.

Authors:  Farnaz Mohajertehran; Hossein Ayatollahi; Kamran Khazaeni; Mohammad-Taghi Shakeri; Nooshin Mohtasham
Journal:  Iran J Otorhinolaryngol       Date:  2018-09

9.  Downregulation of miR‑505‑3p predicts poor bone metastasis‑free survival in prostate cancer.

Authors:  Yubo Tang; Bowen Wu; Shuai Huang; Xinsheng Peng; Xing Li; Xiufang Huang; Wei Zhou; Peigen Xie; Peiheng He
Journal:  Oncol Rep       Date:  2018-10-25       Impact factor: 3.906

10.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

View more
  4 in total

1.  MicroRNAs as the Potential Regulators of SARS-CoV-2 Infection and Modifiers of the COVID-19 Clinical Features.

Authors:  A N Kucher; Iu A Koroleva; A A Zarubin; M S Nazarenko
Journal:  Mol Biol       Date:  2022-02-12       Impact factor: 1.540

2.  COVID-19, Anti-NMDA Receptor Encephalitis and MicroRNA.

Authors:  Hsiuying Wang
Journal:  Front Immunol       Date:  2022-03-22       Impact factor: 7.561

Review 3.  miRNA expression in COVID-19.

Authors:  Kiarash Roustai Geraylow; Romina Hemmati; Sepideh Kadkhoda; Soudeh Ghafouri-Fard
Journal:  Gene Rep       Date:  2022-07-16

Review 4.  miRNAs; a novel strategy for the treatment of COVID-19.

Authors:  Hao Ying; Mohsen Ebrahimi; Mona Keivan; Seyed Esmaeil Khoshnam; Sarvenaz Salahi; Maryam Farzaneh
Journal:  Cell Biol Int       Date:  2021-07-05       Impact factor: 4.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.